Gut bugs linked to bone loss in parathyroid disease
NCT ID NCT04948671
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether the types of bacteria in the gut can predict bone loss in people with primary hyperparathyroidism, a condition where the parathyroid glands produce too much hormone. Researchers planned to analyze gut bacteria and immune system markers in 25 patients with and without bone problems. The goal was to see if gut bacteria could be used as a screening tool to identify those at risk, but the study was terminated early.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could show that analyzing gut bacteria helps identify which patients with primary hyperparathyroidism will develop bone loss, potentially leading to new prevention strategies.
- What could go wrong
- This is a small, terminated observational study with only 25 participants. It does not test any treatment, so any findings would need much larger studies to confirm.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
25 people
The number who actually took part.
- Started
-
Nov 2021
- Finished
-
Feb 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
We will enroll in the project 90 patients affected by Primary hyperparathyroidism
- Ages
-
30 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * diagnosis of primary hyperparathyroidism clinically established * willing and able to give written informed consent * age range 30-80 years * commitment not to use any products that may influence the study outcome * ability to understand and comply with the requirements of the study. Exclusion Criteria: * impossibility to carry out DXA * type 1 and 2 diabetes mellitus * malabsorption * alcohol abuse * renal or hepatic insufficiency * history of any malignancies * use of probiotic supplement within four weeks prior to baseline * use within the past 8 weeks of medication with known influences on the immune or skeletal system * use of antibiotics during the previous two months or frequent user of antibiotics * secondary hyperparathyroidism * use of glucocorticoids or cinacalcet * history of immunological or bone-related disorders
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Hyperparathyroidism, primary are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Patrizia D'amelio
Lausanne, Switzerland, 1012, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.